RxDoctor Payments Data

Robin Morrison, APRN

Family · Memphis, TNNPI 1093827560

Payments from drug & device makers

$13,300in general payments, 2019–2025

Across 425 payments — averaging $31.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • Corcept Therapeutics$1K
  • Medtronic$839
  • Insulet Corporation$832
  • plus $6K from 37 others

What the payments were for

  • Food & beverage$13,241100%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,300 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$72,990
Medicare patients
183
Services billed
2,759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide314$451,393
JardianceEmpagliflozin133$125,914
MounjaroTirzepatide99$110,549
Tresiba Flextouch U-200Insulin Degludec58$108,295
FarxigaDapagliflozin Propanediol80$87,083
TrulicityDulaglutide72$85,164
ForteoTeriparatide12$48,441
Humulin R U-500 KwikpenInsulin Regular, Human26$39,567
KerendiaFinerenone26$36,611
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/721$32,463
Humalog Kwikpen U-200Insulin Lispro12$31,135
Janumet XrSitagliptin Phos/Metformin Hcl27$22,819
VascepaIcosapent Ethyl27$22,357
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$21,810
Novolog FlexpenInsulin Aspart72$20,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,888$474,265359 claims
Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Humulin 70-30$1,415$251,336219 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy$178$165,261182 claims
AstraZenecaFarxiga$434$87,08380 claims
BayerKerendia$545$36,61126 claims
AbbVieSynthroid$158$4,22745 claims
Sanofi-aventis U.S. LLCLantus$425$2,50028 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$36$2,187198 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →